USA flag logo/image

An Official Website of the United States Government

A.

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
1393
Program Year/Program:
1984 / SBIR
Agency Tracking Number:
1393
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
C-MOTION, INC.
C-MOTION, INC. 15821A CRABBS BRANCH WAY ROCKVILLE, MD 20855
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1984
Title: A.
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

A. WE PROPOSE TO DEVELOP A METHODOLOGY BY WHICH THE GENES CODING FOR DISEASE-SPECIFIC ANTIGENS CAN BE RAPIDLY CLONED USING RECOMBINANT DNA TECHNIQUES. THE SYSTEM LENDS ITSELF TO HIGH LEVEL EXPRESSION OF THESE ANTIGENS AS HYBRID PROTEINS, WHICH FACILITATES PRODUCTION OF ANTIBODIES TO THE ANTIGENS. WITH BOTH ANTIGEN AND ANTIBODY, IMMUNODIAGNOSTIC TESTS CAN BE PRODUCED FOR DETECTION OF THESE ANTIGENS IN CLINICAL SAMPLES. THIS SYSTEM, ENCOMPASSING RECOMBINANT DNA AND IMMUNODIAGNOSTIC TECHNIQUES, CAN POTENTIALLY DISCOVER LARGE NUMBERS OF DISEASE SPECIFIC ANTIGENS. A SPECTRUM OF ANTIGENS, SPECIFIC FOR ONE DISEASE, AND TESTS FOR THEM, COULD HAVE CONSIDERABLE DIAGNOSTIC AND THERAPEUTIC VALUE. B. IN PHASE I A CDNA LIBRARY WILL BE CONSTRUCTED FROM AN ESTABLISHED HUMAN LEUKEMIA CELL LINE SUCH AS ACUTE LYMPHOBLASTIC LEUKEMIA (ALL). CLONES CARRYING LEUKEMIA SPECIFIC SEQUENCES WILL BE IDENTIFIED BY DIFFERENTIAL SCREENING WITH PROBES FROM NORMAL LEUKOCYTE CDNA AND PROBES FROM ALL CELL LINE-DERIVED CDNA. CLONING WILL BE INTO THE LAMBDAGTLL EXPRESSION VECTOR. CLONES CARRYING LEUKEMIA SPECIFIC DNA CAN BE INDUCED, WHICH, WITH THE LAMBDAGTLL SYSTEM, WILL LEAD TO EXPRESSION OF SUBSTANTIAL AMOUNTS OF THE ANTIGEN FUSED TO B-GALACTOSIDASE (HYBRID PROTEINS). BECAUSE OF THEIR LARGE SIZE, THE PROTEINS CAN BE EASILY PURIFIED AND USED TO RAISE SPECIFIC ANTISERA. C. PHASE II WILL BE CHARACTERIZATION OF THE CLONED, EXPRESSED ANTIGENS AND THEIR COGNATE ANTIBODIES. WITH THE SPECIFIC ANTISERA, HISTOLOGICAL AND IMMUNOLOGICAL TESTS WILL BE CARRIED OUT TO IDENTIFY THOSE ANTIGENS SPECIFIC FOR THE ALL CELL LINE. IN ADDITION, OTHER CELL LINES, INCLUDING DIFFERENT ESTABLISHED LEUKEMIA CELL LINES, WILL BE TESTED FOR THE PRESENCE OF THESE ANTIGENS. IN PARALLEL, DIAGNOSTIC TESTS WOULD BE DEVELOPED FOR THESE ANTIGENS, WITH THE GOAL OF USING THEM FOR CLINICAL DIAGNOSTIC RESEARCH. D. THE USE OF RECOMBINANT DNA TECHNIQUES GIVES THIS METHODOLOGY THE POWER TO FIND SUBSTANTIAL NUMBERS OF, AS YET, UNIDENTIFIED LEUKEMIA ASSOCIATED ANTIGENS. THIS COULD LEAD TO DISCOVERY OF ANTIGENS USEFUL IN EARLY DIAGNOSIS AND TREATMENT OF A SPECIFIC LEUKEMIA, AND HAS THE POTENTIAL OF DISCOVERING AN ANTIGEN(S) SPECIFIC FOR MORE THAN ONE LEUKEMIA. THIS GENERAL METHODOLOGY COULD BE APPLIED TO THE STUDY OF ANY SPECIFIC DISEASE. REFER TO: NATIONAL CANCER INSTITUTE, DIVISION OF CANCER BIOLOGY AND DIAGNOSIS

Principal Investigator:

Donald w. bowden
SENIOR STAFF SCIENTIST
0

Business Contact:

Small Business Information at Submission:

Collaborative Research Inc
128 Spring Street Lexington, MA 02173

EIN/Tax ID: 522053087
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No